The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy
Open accessAbstract
Purpose: Childhood cancer survivors (CCSs) are at increased risk for subsequent malignant neoplasms (SMNs). We evaluated the long-term risk of SMNs in a well-characterized cohort of 5-year CCSs, with a particular focus on individual chemotherapeutic agents and solid cancer risk. Methods: The Dutch Childhood Cancer Oncology Group–Long-Term Effects After Childhood Cancer cohort includes 6,165 5-year CCSs diagnosed between 1963 and 2001 in the Netherlands. SMNs were identified by linkages with the Netherlands Cancer Registry, the Dutch Pathology Registry, and medical chart review. We calculated standardized incidence ratios, excess absolute risks, and cumulative incidences. Multivariable Cox proportional hazard regression analyses were used to evaluate treatment-associated risks for breast cancer, sarcoma, and all solid cancers. Results: After a median follow-up of 20.7 years (range, 5.0 to 49.8 years) since first diagnosis, 291 SMNs were ascertained in 261 CCSs (standardized incidence ratio, 5.2; 95% CI, 4.6 to 5.8; excess absolute risk, 20.3/10,000 person-years). Cumulative SMN incidence at 25 years after first diagnosis was 3.9% (95% CI, 3.4% to 4.6%) and did not change noticeably among CCSs treated in the 1990s compared with those treated earlier. We found dose-dependent doxorubicin-related increased risks of all solid cancers ( P trend < .001) and breast cancer ( P trend < .001). The doxorubicin-breast cancer dose response was stronger in survivors of Li-Fraumeni syndrome–associated childhood cancers (leukemia, CNS, and non-Ewing sarcoma) versus survivors of other cancers ( P difference = .008). In addition, cyclophosphamide was found to increase sarcoma risk in a dose-dependent manner ( P trend = .01). Conclusion: The results strongly suggest that doxorubicin exposure in CCSs increases the risk of subsequent solid cancers and breast cancer, whereas cyclophosphamide exposure increases the risk of subsequent sarcomas. These results may inform future childhood cancer treatment protocols and SMN surveillance guidelines for CCSs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone Sarcomas Linked to Radiotherapy and Chemotherapy in Children
Tucker, M. A., D'Angio, G. J., Boice, J. D., Strong, L. C., Li, F. P., Stovall, M., Stone, B. J., Green, D. M., Lombardi, F., Newton, W., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171002 · Cited by 765
Cited by
Childhood cancer: Survival, treatment modalities, late effects and improvements over time
Erdmann, F., Frederiksen, L. E., Bonaventure, A., Mader, L., Hasle, H., Robison, L. L., & Winther, J. F. (2021) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101733 · Cited by 413
New insights into the activities and toxicities of the old anticancer drug doxorubicin
van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2021) · The FEBS Journal · doi:10.1111/febs.15583 · Cited by 410
Boguszewski, M. C. S., Boguszewski, C. L., Chemaitilly, W., Cohen, L. E., Gebauer, J., Higham, C., Hoffman, A. R., Polak, M., Yuen, K. C. J., Alos, N., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1186 · Cited by 117
Self-citationRyder-Burbidge, C., Diaz, R. L., Barr, R. D., Gupta, S., Nathan, P. C., McKillop, S. J., & Fidler-Benaoudia, M. M. (2021) · Cancers · doi:10.3390/cancers13194870 · Cited by 65
Clinical and epidemiological observations on individual radiation sensitivity and susceptibility
Seibold, P., Auvinen, A., Averbeck, D., Bourguignon, M., Hartikainen, J. M., Hoeschen, C., Laurent, O., Noël, G., Sabatier, L., Salomaa, S., et al. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1665209 · Cited by 56
Metadata
- Authors
- Teepen, J. C., van Leeuwen, F. E., Tissing, W. J., van Dulmen-den Broeder, E., van den Heuvel-Eibrink, M. M., van der Pal, H. J., Loonen, J. J., Bresters, D., Versluys, B., Neggers, S. J. C. M. M., Jaspers, M. W. M., Hauptmann, M., van der Heiden-van der Loo, M., Visser, O., Kremer, L. C. M., Ronckers, C. M., & the DCOG LATER Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2017-07-10
- Volume
- 35
- Issue
- 20
- Pages
- 2288-2298
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2618647272
- Cited by
- 222
- References
- 1
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. https://app.cochat.ai/papers/10.1200/jco.2016.71.6902
- The paper
- Teepen, J. C., van Leeuwen, F. E., Tissing, W. J., van Dulmen-den Broeder, E., van den Heuvel-Eibrink, M. M., van der Pal, H. J., Loonen, J. J., Bresters, D., Versluys, B., Neggers, S. J. C. M. M., Jaspers, M. W. M., Hauptmann, M., van der Heiden-van der Loo, M., Visser, O., Kremer, L. C. M., Ronckers, C. M., & the DCOG LATER Study Group. (2017). Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.71.6902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.